Olema Pharmaceuticals, Inc. logo OLMA - Olema Pharmaceuticals, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 8
HOLD 0
SELL 0
STRONG
SELL 0
| PRICE TARGET: $41.88 DETAILS
HIGH: $48.00
LOW: $35.00
MEDIAN: $41.50
CONSENSUS: $41.88
UPSIDE: 206.14%

Stock News

Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting

Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting

OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse events OP-3136 shows evidence of anti-tumor activity across multiple solid tumor types Data support the ongoing Phase 1 evaluation of OP-3136 as a monotherapy and in combination with fulvestrant and palazestrant SAN FRANCISCO, May 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced preliminary clinical data from the Phase 1 study of OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor. The data will be presented in a poster presentation on May 30, 2026 at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois.

May 21, 2026 01:00 PM • globenewswire.com
Olema Oncology to Participate in Upcoming Investor Conferences

Olema Oncology to Participate in Upcoming Investor Conferences

SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: TD Cowen 7 th Annual Oncology Innovation Summit Date and Time: May 26, 2026 at 12:30 p.m. ETFormat: Fireside ChatLocation: Virtual Jefferies Global Healthcare Conference Date and Time: June 3, 2026 at 8:45 a.m.

May 19, 2026 12:30 PM • globenewswire.com
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to five new employees to purchase an aggregate of 154,700 shares of the Company's common stock, effective as of May 1, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

May 04, 2026 12:30 PM • globenewswire.com
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting

Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting

SAN FRANCISCO, April 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present initial clinical data from the Phase 1 study of OP-3136 in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 29-June 2 in Chicago, Illinois. The Company will also present a trial-in-progress poster for the Phase 3 OPERA-02 trial.

Apr 21, 2026 12:01 PM • globenewswire.com
Analyzing Olema Pharmaceuticals (NASDAQ:OLMA) and Ligand Pharmaceuticals (NASDAQ:LGND)

Analyzing Olema Pharmaceuticals (NASDAQ:OLMA) and Ligand Pharmaceuticals (NASDAQ:LGND)

Olema Pharmaceuticals (NASDAQ: OLMA - Get Free Report) and Ligand Pharmaceuticals (NASDAQ: LGND - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership. Earnings and Valuation This table compares Olema Pharmaceuticals

Apr 12, 2026 09:44 PM • defenseworld.net
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, April 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 188,500 shares of the Company's common stock, effective as of April 1, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

Apr 02, 2026 12:30 PM • globenewswire.com
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer Advanced enrollment in the OPERA-02 pivotal Phase 3 trial of palazestrant in combination with ribociclib in patients with frontline ER+/HER2- metastatic breast cancer Initiated the Phase 1b/2 study of palazestrant in combination with Pfizer's novel CDK4 inhibitor, atirmociclib, in patients with ER+/HER2- metastatic breast cancer Continued enrollment in the Phase 1 clinical study of OP-3136 in breast cancer and other solid tumors, with initial clinical data expected in Q2 2026 Generated $218.5 million in gross proceeds from a follow-on public offering, further strengthening the Company's balance sheet; ended 2025 with $505.4 million in cash, cash equivalents, and marketable securities Transformation into a fully-integrated oncology company underway in preparation for the Company's first potential commercial launch in late 2027 SAN FRANCISCO, March 16, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the fourth quarter and full year ended December 31, 2025. “2025 was a year of strong execution across the business as we advanced palazestrant as a differentiated endocrine therapy across multiple regimens, highlighted by continued enrollment and strong investigator interest in our OPERA-01 and OPERA-02 trials,” said Sean P.

Mar 16, 2026 03:00 AM • globenewswire.com
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, March 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 205,000 shares of the Company's common stock, effective as of March 2, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

Mar 03, 2026 11:30 AM • globenewswire.com
Olema Pharmaceuticals CEO Teases Fall OPERA-01 Readout, Q2 KAT6 Data and CFO/COO Exit

Olema Pharmaceuticals CEO Teases Fall OPERA-01 Readout, Q2 KAT6 Data and CFO/COO Exit

Olema Pharmaceuticals (NASDAQ: OLMA) is focused on developing endocrine therapies aimed at improving outcomes for patients with estrogen receptor (ER)-positive, HER2-negative breast cancer, CEO Sean Bohen said during a company discussion hosted by Brad Canino. Bohen described the disease area as a large unmet need, noting that breast cancer is the most common cancer diagnosis in

Feb 15, 2026 08:02 PM • defenseworld.net
Olema Oncology to Participate in Upcoming Investor Conferences

Olema Oncology to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: Guggenheim Securities Emerging Outlook: Biotech Summit Date and Time: February 11, 2026 at 10:00 a.m. ET Format: Fireside ChatLocation: New York, NY Citi's 2026 Virtual Oncology Leadership Summit Date and Time: February 19, 2026 at 1:00 p.m.

Feb 04, 2026 11:30 AM • globenewswire.com
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 24,000 shares of the Company's common stock, effective as of February 2, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

Feb 03, 2026 11:30 AM • globenewswire.com

Price Targets